We also followed up 10 glioma patients sera (5 seropositive patients and 5 seronegative patients of preoperative) autoantibody levels during postoperative 30 days and the tumor recurrence to validate the changing of anti‐MGMT‐02 peptide autoantibody level (Figure 5). This evidence concerns the gene MGMT and neoplasm.